NRSN NEUROSENSE THERAPEUTICS LTD revenue, earnings and financials
For the fiscal year ended December 2025 revenue was n/a.
NRSN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$11.1M, net income −$11.1M (margin n/a), EPS −$0.44
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$9.90M, net income −$10.2M (margin n/a), EPS −$0.54
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$12.0M, net income −$10.1M (margin n/a), EPS −$0.74
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$10.6M, net income −$10.5M (margin n/a), EPS −$0.91
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$2.99M, net income −$3.22M (margin n/a), EPS −$0.52
NRSN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$7.67M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$10.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$8.35M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.62M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.54M, share buybacks n/a
NRSN balance sheet
- Dec 31, 2025: cash $166K, total assets $1.03M, total liabilities $2.59M, shareholders' equity −$1.56M
- Jun 30, 2025: cash $666K, total assets $1.68M, total liabilities $2.20M, shareholders' equity −$519K
- Dec 31, 2024: cash $3.38M, total assets $4.58M, total liabilities $1.99M, shareholders' equity $2.58M
- Jun 30, 2024: cash $1.21M, total assets $1.84M, total liabilities $3.54M, shareholders' equity −$1.70M
- Dec 31, 2023: cash $2.64M, total assets $3.19M, total liabilities $4.94M, shareholders' equity −$1.76M
- Dec 31, 2022: cash $3.54M, total assets $7.72M, total liabilities $1.87M, shareholders' equity $5.84M
Is NRSN profitable?
No. NEUROSENSE THERAPEUTICS LTD lost $11.1M in its latest fiscal year.